BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32367497)

  • 1. Management of Older Adults with Mantle Cell Lymphoma.
    Romancik JT; Cohen JB
    Drugs Aging; 2020 Jul; 37(7):469-481. PubMed ID: 32367497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.
    Buege MJ; Kumar A; Dixon BN; Tang LA; Pak T; Orozco J; Peterson TJ; Maples KT
    Ann Pharmacother; 2020 Sep; 54(9):879-898. PubMed ID: 32079411
    [No Abstract]   [Full Text] [Related]  

  • 3. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.
    Shah BD; Martin P; Sotomayor EM
    Cancer Control; 2012 Jul; 19(3):227-35. PubMed ID: 22710898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
    Epstein-Peterson ZD; Drill E; Aypar U; Batlevi CL; Caron P; Dogan A; Drullinsky P; Gerecitano J; Hamlin PA; Ho C; Jacob A; Joseph A; Laraque L; Matasar MJ; Moskowitz AJ; Moskowitz CH; Mullins C; Owens C; Salles G; Schöder H; Straus DJ; Younes A; Zelenetz AD; Kumar A
    Haematologica; 2024 Apr; 109(4):1149-1162. PubMed ID: 37646671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Therapies in the Treatment of Mantle Cell Lymphoma.
    Thomas CJ; Carvajal V; Barta SK
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.
    Monga N; Tam C; Garside J; Davids MS; Ward K; Quigley J; Parisi L; Tapprich C
    Crit Rev Oncol Hematol; 2021 Feb; 158():103212. PubMed ID: 33383209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mantle cell lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJM; Dreyling M
    Crit Rev Oncol Hematol; 2020 Sep; 153():103038. PubMed ID: 32739830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis of targeted therapies for diffuse large B cell lymphoma.
    Wang J; Huang J; Zeng Q
    BMC Cancer; 2020 Dec; 20(1):1218. PubMed ID: 33308179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First Line Systemic Treatment for MALT Lymphoma-Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna.
    Kiesewetter B; Simonitsch-Klupp I; Mayerhoefer ME; Dolak W; Lukas J; Raderer M
    Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33256131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing Multiple Myeloma in the Face of Drug-Induced Adverse Drug Reaction.
    Dougherty JA; Elder CT
    J Pharm Pract; 2022 Jun; 35(3):500-504. PubMed ID: 33317373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex-Specific Associations Between Bipolar Disorder Pharmacological Maintenance Therapies and Inpatient Rehospitalizations: A 9-Year Swedish National Registry Study.
    Ragazan DC; Eberhard J; Berge J
    Front Psychiatry; 2020; 11():598946. PubMed ID: 33262715
    [No Abstract]   [Full Text] [Related]  

  • 13. Optical coherence tomography angiography characteristics in Waldenström macroglobulinemia retinopathy: A case report.
    Li J; Zhang R; Gu F; Liu ZL; Sun P
    World J Clin Cases; 2020 Dec; 8(23):6071-6079. PubMed ID: 33344607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second haploidentical stem cell transplantation for primary graft failure.
    Giammarco S; Raiola AM; Di Grazia C; Bregante S; Gualandi F; Varaldo R; Chiusolo P; Sora F; Sica S; Laurenti L; Metafuni E; Innocenti I; Autore F; Murgia B; Bacigalupo A; Angelucci E
    Bone Marrow Transplant; 2021 Jun; 56(6):1291-1296. PubMed ID: 33328569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients.
    Eltahir M; Fletcher E; Dynesius L; Jarblad JL; Lord M; Laurén I; Zekarias M; Yu X; Cragg MS; Hammarström C; Levedahl KH; Höglund M; Ullenhag G; Mattsson M; Mangsbo SM
    Int Immunopharmacol; 2021 Jan; 90():107226. PubMed ID: 33316742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment With Bortezomib for Refractory and Complicated Acquired Thrombotic Thrombocytopenic Purpura in an Adolescent Girl.
    Azapağasi E; Uysal Yazici M; Eroğlu N; Albayrak M; Kucur Ö; Fettah A
    J Pediatr Hematol Oncol; 2021 May; 43(4):e587-e591. PubMed ID: 33306607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy].
    Nakamura A; Yamaguchi T; Ito R; Kawakami K
    Rinsho Ketsueki; 2020; 61(11):1600-1604. PubMed ID: 33298653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcome of ABO-Incompatible Kidney Transplantation in Patients Treated With Low-Dose Rituximab Regimen.
    Sasaki H; Hotta K; Mitsuke A; Fukasawa Y; Tanabe T; Higuchi H; Takada Y; Harada H
    Transplant Proc; 2021 Apr; 53(3):989-994. PubMed ID: 33272650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic drug monitoring of antiinfectives in intensive care unit patients - what's new?].
    König C; Kluge S; Wicha SG
    Dtsch Med Wochenschr; 2020 Dec; 145(24):1764-1769. PubMed ID: 33254251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Resistance Patterns: Review of the Antibiogram of a Surgical Unit in a Public Tertiary Care Hospital of Pakistan.
    Kathia UM; Munir T; Fateh F; Ahmad A; Amjad A; Afzal MF
    Cureus; 2020 Oct; 12(10):e11159. PubMed ID: 33251067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.